Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCroda International Regulatory News (CRDA)

Share Price Information for Croda International (CRDA)

Share Price is delayed by 15 minutes
Get Live Data
3152.00    68.00 (2.20%)
Bid:
3151.00
Ask:
3153.00
Spread: 2.00 (0.063%)
Market Cap: £4.39b
CRDA Live PriceLast checked at - London Stock Exchange

Intraday Croda International Share Chart

Interim Management Statement

24 Apr 2014 07:00

RNS Number : 3766F
Croda International PLC
24 April 2014
 



24 April 2014

 

Croda International Plc

 

AGM and Interim Management Statement

 

PROFITABILITY IMPROVED DESPITE ADVERSE CURRENCY TRANSLATION

 

 

Croda International Plc today announces its Interim Management Statement for the period since 31 December 2013.

 

Trading

 

The modest but improving growth trend in underlying sales seen in the second half of 2013 continued through the first quarter of 2014, despite the disruption caused by the severe weather in North America and difficult economic conditions in South America. On a constant currency basis, Group turnover was up 2.9% with acquisitions contributing 1.6% to this total. However, adverse currency translation of 6.1% meant that reported sales in sterling were down 3.2% to £274.0m (2013: £283.1m).

 

Group operating profit increased 1.0% to £68.7m (2013: £68.0m). Operating margins increased to 25.1% (2013: 24.0%), reflecting favourable product mix. Return on sales increased to 33.3% (2013: 31.1%) in Consumer Care and to 19.0% (2013: 17.0%) in Performance Technologies as both divisions continued to benefit from strong underlying demand for high value products. Industrial Chemicals' return on sales reduced to 4.7% (2013: 9.1%), reflecting the integration of Sipo and weaker commodity margins generally.

 

Pre-tax profits increased slightly to £65.2m (2013: £65.1m) with a stronger underlying performance offset by a £3.5m impact from adverse currency translation.

 

On a divisional basis, underlying Consumer Care sales decreased by 0.6%. Crop Care was impacted by heavy snow in North America during January and February and weak sales into Eastern Europe. Weak sales in North America and challenging economic conditions in South America were the main reasons behind modest underlying sales declines in Personal Care. Health Care growth was strong in almost all geographies. A further 0.5% contribution to sales growth came from acquisitions.

 

Underlying sales in Performance Technologies were up 3.7%, continuing the improved trend seen in the final quarter of 2013. Business in Asia was particularly strong. All business areas apart from Home Care saw good sales growth. The Sipo acquisition added an additional 1.7% to turnover.

 

Underlying Industrial Chemicals sales were up 2.7% and again, Sipo added a further 7.2% to the growth.

 

Financial Position

 

There has been no significant change in Croda's financial position during the period. Interest costs in the quarter were slightly higher than 2013 due to the consolidation of 100% of Sipo's debt.

 

Underlying cash generation was again strong in the quarter, with net debt falling £13.6m to £188.6m after paying over £20m into the UK pension fund in January.

 

Outlook

 

We expect the modest improvement in underlying sales growth seen in the first quarter to continue. However, adverse currency translation is expected to remain an issue and consequently, second quarter performance is likely to be similar to that seen in the first quarter. The Board is confident that the Group has the right strategy in place to continue to drive profitable underlying growth.

 

 

For further information please contact:

 

Steve Foots/ Sean Christie

Croda International Plc

 

Charlie Armitstead/ Rosie Oddy

Pendomer Communications

 

 

Tel: 01405 860551

 

 

Tel: 020 3603 5220

 

 

The company will host a conference call for analysts at 8.00am (BST) today:

 

Dial-In: +44 (0) 203 426 2888

Please quote "Croda International"to gain access to the call

 

 

Croda International Plc

Unaudited income statement for continuing operations

31 March 2014

 

3 months to

3 months to

31 March

31 March

2014

2013

Change

Revenue

Consumer Care

148.4

158.4

-6.3%

Performance Technologies

93.8

93.9

-0.1%

Industrial Chemicals

31.8

30.8

+3.2%

274.0

283.1

-3.2%

Adjusted operating profit1

Consumer Care

49.4

49.2

+0.4%

Performance Technologies

17.8

16.0

+11.3%

Industrial Chemicals

1.5

2.8

-46.4%

68.7

68.0

+1.0%

Net bank and loan interest payable

(2.3)

(1.7)

Net retirement benefit scheme financing

(1.2)

(1.2)

Adjusted profit before tax1

65.2

65.1

+0.2%

Operating margin

25.1%

24.0%

 

Analysis of turnover uplift for continuing operations:

 

Constant

Currency

Underlying

Acquisitions

Currency

translation

Total

Consumer Care

-0.6%

+0.5%

-0.1%

-6.2%

-6.3%

Performance Technologies

+3.7%

+1.7%

+5.4%

-5.5%

-0.1%

Industrial Chemicals

+2.7%

+7.2%

+9.9%

-6.7%

+3.2%

Total

+1.3%

+1.6%

+2.9%

-6.1%

-3.2%

 

 

 

1 Continuing operations before exceptional items, acquisition costs and amortisation/write off of intangible assets arising on acquisition.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSMMGZDRFNGDZM
Date   Source Headline
11th Jun 20262:58 pmRNSDirector/PDMR Shareholding
11th Jun 20269:15 amRNSDirector Declaration
1st Jun 20261:46 pmRNSDirector/PDMR Shareholding
29th May 20264:06 pmRNSDirector/PDMR Shareholding
29th May 20263:10 pmRNSDirector/PDMR Shareholding
29th May 20261:53 pmRNSDirector/PDMR Shareholding
29th May 20261:52 pmRNSDirector/PDMR Shareholding
29th May 20261:45 pmRNSDirector/PDMR Shareholding
15th May 20269:23 amRNSDirector/PDMR Shareholding
12th May 202612:10 pmRNSDirector/PDMR Shareholding
6th May 20261:21 pmRNSDirector/PDMR Shareholding
23rd Apr 202611:20 amRNSResult of AGM
22nd Apr 20267:00 amRNSFirst quarter 2026 sales in line with expectations
13th Apr 20261:41 pmRNSDirector/PDMR Shareholding
31st Mar 202611:48 amRNSHolding(s) in Company
26th Mar 20264:34 pmRNSDirector/PDMR Shareholding
18th Mar 20263:31 pmRNSDirector/PDMR Shareholding
18th Mar 20263:30 pmRNSDirector/PDMR Shareholding
18th Mar 20263:27 pmRNSDirector/PDMR Shareholding
18th Mar 20263:25 pmRNSDirector/PDMR Shareholding
18th Mar 20263:23 pmRNSDirector/PDMR Shareholding
18th Mar 20263:23 pmRNSDirector/PDMR Shareholding
18th Mar 20263:20 pmRNSDirector/PDMR Shareholding
16th Mar 20261:36 pmRNSAnnual Financial Report
16th Mar 20261:36 pmRNSAnnual Financial Report
11th Mar 202611:28 amRNSDirector/PDMR Shareholding
11th Mar 202611:28 amRNSDirector/PDMR Shareholding
6th Mar 20261:32 pmRNSDirector/PDMR Shareholding
3rd Mar 20265:13 pmRNSHolding(s) in Company
24th Feb 20267:00 amRNSResults for the year ended 31 December 2025
11th Feb 20262:59 pmRNSDirector/PDMR Shareholding
13th Jan 20262:47 pmRNSDirector/PDMR Shareholding
9th Jan 20267:00 amRNSDirector Declaration
11th Dec 202511:30 amRNSDirector/PDMR Shareholding
11th Nov 202511:19 amRNSDirector/PDMR Shareholding
16th Oct 20257:00 amRNSThird quarter 2025 sales update
14th Oct 20251:58 pmRNSDirector/PDMR Shareholding
8th Oct 20254:26 pmRNSDirector/PDMR Shareholding
1st Oct 20253:45 pmRNSDirector/PDMR Shareholding
18th Sep 20253:49 pmRNSHolding(s) in Company
12th Sep 202510:11 amRNSDirector/PDMR Shareholding
11th Sep 20253:54 pmRNSDirector/PDMR Shareholding
29th Aug 20253:58 pmRNSHolding(s) in Company
29th Aug 202511:03 amRNSHolding(s) in Company
27th Aug 20251:58 pmRNSHolding(s) in Company
22nd Aug 20254:24 pmRNSDirector/PDMR Shareholding
22nd Aug 202511:55 amRNSDirector/PDMR Shareholding
14th Aug 20259:10 amRNSDirector/PDMR Shareholding
12th Aug 202511:42 amRNSDirector/PDMR Shareholding
7th Aug 20259:16 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.